CVMNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
CEL SCI CORP
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.65−0.14 (-7.82%)
Close on Oct 19, 2026
- Market cap
- $19.99M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$7.20 (−81.36%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $19.99M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.82
- Dividend yield
- –
- Free cash flow yield
- -83.79%
Fundamentals
- Net income
- -$22.70M
- EPS, diluted
- -$6.27
- Free cash flow
- -$16.75M
- Book value per share
- $0.90
- Diluted shares
- 12M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$22.29M
Net income
-$22.70M
EPS, diluted
–
Free cash flow
-$16.75M
Reported periodTrailing twelve months